Edward C. English
Geen lopende functies
Vermogen: 6 482 $ op 31-03-2024
Profiel
Edward C.
English worked as Chief Financial Officer, Treasurer & VP at Praecis Pharmaceuticals, Inc. He then worked as Manager at KPMG LLP.
After that, he worked as Vice President & Controller at AMAG Pharmaceuticals, Inc. and later as CAO, Vice President-Finance & Administration at Tesaro, Inc. He also worked as CAO, VP-Finance, Accounting & Treasury at Xilio Therapeutics, Inc. Mr. English holds a graduate degree and an MBA from Northeastern University and an undergraduate degree from Georgetown University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
XILIO THERAPEUTICS INC
0.02% | 01-01-2023 | 6 002 ( 0.02% ) | 6 482 $ | 31-03-2024 |
Eerdere bekende functies van Edward C. English
Bedrijven | Functie | Einde |
---|---|---|
XILIO THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 31-01-2023 |
TESARO INC | Director of Finance/CFO | 25-05-2014 |
AMAG PHARMACEUTICALS, INC. | Director of Finance/CFO | 02-08-2011 |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | Director of Finance/CFO | - |
Opleiding van Edward C. English
Northeastern University | Graduate Degree |
Georgetown University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
XILIO THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | Health Technology |
Tesaro, Inc.
Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Commercial Services |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |